Polymorphism of Virulence Factor Genes Prn and Fim of Bordetella Pertussis Clinical Isolates in Iran

Document Type : Original Research

Authors
1 Department of Microbiology, Faculty of Medicine, Shahed University, Tehran, Iran
2 Molecular Microbiology Research Center (MMRC), Shahed University, Tehran, Iran
3 Department of Microbiology, Pasteur Institute of Iran, Tehran, Iran
Abstract
Objectives: Bordetella pertussis is a Gram-negative coccobacillus bacterium which is the causative agent of whooping cough. In recent years, the number of whooping cough cases has been rised. This bacterium has important virulence factors such as fimbriae and pertactin. In this study, polymorphism of Serotype 2 and 3 fimbriae genes and 2 Regions of pertactin gene were surveyed.

Materials & Methods: Totally, 20 B. pertussis clinical isolates were tested. DNA was extracted using the kit. Serotypes 2 and 3 fimbriae genes and pertactin Region 1 and 2 were identified using PCR method; finally, 13 samples were randomly sequenced.

Findings: No mutation was observed in the pertactin Region 2. In relation to the region1 of pertactin, 77% and 23% of the strains had prn2 and prn1 alleles, respectively. In relation to fim2 gene, 70% and 30% of the strains had fim2-2 and fim2-1 alleles, respectively. Also, in relation to fim3 gene, 70% and 30% of the strains carried fim3B and fim3A alleles, respectively.

Conclusion: In general, the present study results were similar to those of the previous studies conducted in Iran, but there were some differences in fim2 gene polymorphism so that the dominant allele changed from fim2-1 to fim2-2. Considering the fact that vaccine strains of Bp134 and Bp509 carry fim3A allele, which is different from the dominant circulating allele (fim3B), it is suggested that strains more similar to the dominant circulating strains should be used in designing vaccines.

Keywords

Subjects


1. Brooks GF, Jawetz E, Melnick JL AE. Jawetz, Melnick, & Adelberg’s medical microbiology. 26 th Vol. New York: New York : McGraw-Hill Medical; 2013. 877 p.
2. Sealey KL, Belcher T PA. Bordetella pertussis epidemiology and evolution in the light of pertussis resurgence. Infect Genet Evol. 2016;40:136–43.
3. Hegerle N GN. Epidemiology of whooping cough and typing of Bordetella pertussis. Futur Microbiol. 2013;8(11):1391–403.
4. Fast Facts Centers for Disease Control and Prevention. National Center for Immunization and Respiratory Diseases Pertussis (whooping cough). 2015.
5. Dorji D, Mooi F, Yantorno O, Deora R, Graham RM, Mukkur TK. Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance. Med Microbiol Immunol. 2018;207:3–26.
6. Bowden KE, Weigand MR, Peng Y, Cassiday PK, Sammons C, Knipe K, et al. Genome Structural Diversity among 31 Bordetella pertussis Isolates from Two Recent U.S. Whooping Cough Statewide Epidemics. Mol Biol Physiol. 2016;1(3):e00036-16.
7. Alamaw SD, Kassa AW, Gelaw YA. Pertussis outbreak investigation of Mekdela district, South Wollo zone, Amhara region, North-West Ethiopia. BMC Res Notes. 2017;10:420.
8. Barbosa F, Barnett ED, Gautret P, Schlagenhauf P, Genderen PJJ van, Grobusch MP, et al. Bordetella pertussis infections in travelers: data from the GeoSentinel global network. J Travel Med. 2017;24(3):1–5.
9. Cattelan N, Jennings-Gee J, Dubey P, Yantorno OM, Deora R. Hyperbiofilm Formation by Bordetella pertussis Strains Correlates with Enhanced Virulence Traits. Infect Immun. 2017;85(12):e00373-17.
10. Badiri P, Noofeli M, Noormohammadi Z, Nikbin VS, Shahbazi T. Investigation of Genetic Variations in Virulence Factor Genes ptxC , tcfA , and fhaB of Bordetella pertussis Clinical Isolates and Vaccine Strains in Iran. Infect Epidemiol Microbiol. 2018;4(3):1–6.
11. Nikbin VS, Jannesar Ahmadi N, Hosseinpour M, Nakhost Lotfi M, Shooraj F, Sadeghpour F, et al. Virulence Factors Variation Among Bordetella Pertussis Isolates in Iran. Int J Mol Cell Med. 2015;4(2):138–42.
12. https://lifescience.roche.com/global_en/products/high-pure-pcr-template-preparation-kit.html.
13. Berbers GAM, Greeff SC de, Mooi FR. Improving pertussis vaccination. Hum Vaccin. 2009;5(7):497–503.
14. Mooi Fr, Oirschot H Van, Heuvelman K, Heide Hgj Van Der, Gaastra W, Willems Rjl. Polymorphism in the Bordetella pertussis Virulence Factors P.69/Pertactin and Pertussis Toxin in The Netherlands: Temporal Trends and Evidence for Vaccine-Driven Evolution. Infect Immun. 1998;66(2):670–5.
15. Nikbin VS, Ahmadi NJ, Hosseinpour M, Lotfi MN, Shooraj F, Sadeghpour F, et al. Virulence Factors Variation Among Bordetella Pertussis Isolates in Iran. Int J Mol Cell Med. 2015;4(2):138.
16. Sadeghpour F. Investigation of polymorphism of virulence factors of bordetella pertussis in region 2 of pertactin gene, Fimbria 2 (Fim2) and promoter of pertussis toxin (Ptx promoter) in isolates from suspected cases of pertussis in Iran. Pasteur Institute of Iran; 2014.
17. Godfroid F, Denoël P, Poolman J. Are vaccination programs and isolate polymorphism linked to pertussis re-emergence? Expert Rev Vaccines. 2005;4(5):757–78.
18. Loo IHM van, Heuvelman KJ, King AJ, Mooi FR. Multilocus Sequence Typing of Bordetella pertussis Based on Surface Protein Genes. J Clin Microbiol. 2002;40(6):1994–2001.
19. Weber C, Boursaux-Eude C, Coralie G, Caro V, Guiso N. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J Clin Microbiol. 2001;39(12):4396–403.
20. Amersfoorth SCM van, Schouls LM, Heide HGJ van der, Advani A, Hallander HO, Bondeson K, et al. Analysis of Bordetella pertussis Populations in European Countries with Different Vaccination Policies. J Clin Microbiol. 2005;43(6):2837–2843.
21. Fingermann M, Fernandez J, Sisti F, Rodriguez M, Gatti B, Bottero D, et al. Differences of circulating Bordetella pertussis population in Argentina from the strain used in vaccine production. Vaccine. 2006;24:3513–21.
22. Shuel M, Lefebvre B, Whyte K, Hayden K, De Serres G, Brousseau N, et al. Antigenic and genetic characterization of Bordetella pertussis recovered from Quebec, Canada, 2002-2014_ detection of a genetic shift. Can J Microbiol. 2016;62(5):437–41.
23. Bowden K, Weigand M, Peng Y, Cassiday P, Sammons S, Knipe K, et al. Genome Structural Diversity among 31 Bordetella pertussis Isolates from Two Recent U.S. Whooping Cough Statewide Epidemics. Mol Biol Physiol. 2016;1(3):e00036-16.
24. Pawloski L, Queenan A, Cassiday P, Lynch A, Harrison M, Shang W, et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States. Clin Vaccine Immunol. 2014;21(2):119–25.
25. Borisova O, Kombarova SY, Zakharova NS, Van Gent M, Aleshkin VA, Mazurova I, et al. Antigenic divergence between Bordetella pertussis clinical isolates from Moscow, Russia, and vaccine strains. Clin Vaccine Immunol. 2007;14(3):234–8.